Sorry, you need to enable JavaScript to visit this website.
Skip to main content

This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Adverse event reporting can be found at the bottom of the page

Welcome to the HCP Events Portal

Pfizer Ltd offers a diverse portfolio of medicines across a broad range of therapeutic areas and is committed to supporting the appropriate use of these medicines in patients. Join us at one of our promotional virtual meetings to learn more.

The promotional meetings below are organised and funded by Pfizer and may include reference to Pfizer medicines relevant to agenda topics. Prescribing information for the relevant medicine can be found underneath the meeting information. Adverse event reporting information can be found at the bottom of the page.


Live webinars

Filter By Therapeutic Areas:
Anti-Infectives
Haematology
Haem Oncology
Duration
1 Hr
06
Dec
2021
13:00
  • CRESEMBA®(isavuconazole)
PP-CRB-GBR-1370. November 2021

COVID-19-Associated Pulmonary Aspergillosis (CAPA): What Have We Learnt? - [Content developed in line with Summary of Product Characteristics for Great Britain]

Dr Philip Lewis White
Suggested audience
Consultants
Nurses
Pharmacists
Specialist Registrars
Read more Register Here

CRESEMBA®(isavuconazole) 

Prescribing Information for Great Britain and Adverse Event Reporting 200mg powder for concentrate for solution for infusion and Cresemba 100mg hard capsules

Prescribing Information for Great Britain and Adverse Event Reporting 100 mg Hard Capsules

Prescribing Information for Northern Ireland and Adverse Event Reporting 200mg powder for concentrate for solution for infusion and Cresemba 100mg hard capsules

NVAF
VTE
Duration
1 Hr 30
14
Dec
2021
19:00
  • ELIQUIS®(apixaban) - NVAF & VTE
PP-ELI-GBR-9846. October 2021

Geriatric Giants - [Content developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland]

Dr James Read
Suggested audience
Consultants
General Practitioners
Nurses
Pharmacists
Specialist Registrars
Read more Register Here

ELIQUIS® (apixaban) Prescribing Information and Adverse Event Reporting

Risk Minimisation Materials:
Eliquis Prescriber Guide and Patient Alert Card are aimed at increasing awareness about the potential risk of bleeding with apixaban.
More information on each of these documents can be found at
www.medicines.org.uk/emc/product/2878/rmms (5 mg)
or www.medicines.org.uk/emc/product/4756/rmms (2.5 mg).

NVAF
VTE
Duration
1 Hr 15
14
Dec
2021
19:30
  • ELIQUIS®(apixaban) - NVAF & VTE
PP-ELI-GBR-9858. October 2021

Dilemmas in Anticoagulation: The Frail, The Elderly and The Challenges - [Content developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland]

Dr Michael Jackson Mr Nathan Hutchinson-Jones
Suggested audience
Pharmacists
Read more Register Here

ELIQUIS® (apixaban) Prescribing Information and Adverse Event Reporting

Risk Minimisation Materials:
Eliquis Prescriber Guide and Patient Alert Card are aimed at increasing awareness about the potential risk of bleeding with apixaban.
More information on each of these documents can be found at
www.medicines.org.uk/emc/product/2878/rmms (5 mg)
or www.medicines.org.uk/emc/product/4756/rmms (2.5 mg).

NVAF
VTE
Duration
1 Hr 15
19
Jan
2022
19:30
  • ELIQUIS®(apixaban) - NVAF & VTE
PP-ELI-GBR-9712. September 2021

The Series - Anticoagulation Stewardship: Pulling Pharmacists Together to Deliver Optimal Patient Care - [Content developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland]

Dr Richard Brown Mr Raj R Patel Miss Alison Freemantle Dr Michael Jackson
Suggested audience
Pharmacists
Read more Register Here

ELIQUIS® (apixaban) Prescribing Information and Adverse Event Reporting

Risk Minimisation Materials:
Eliquis Prescriber Guide and Patient Alert Card are aimed at increasing awareness about the potential risk of bleeding with apixaban.
More information on each of these documents can be found at
www.medicines.org.uk/emc/product/2878/rmms (5 mg)
or www.medicines.org.uk/emc/product/4756/rmms (2.5 mg).

NVAF
VTE
Duration
1 Hr 30
25
Jan
2022
19:00
  • ELIQUIS®(apixaban) - NVAF & VTE
PP-ELI-GBR-9878. October 2021

Geriatric Giants 2 - [Content developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland]

Dr James Read
Suggested audience
Consultants
General Practitioners
Nurses
Pharmacists
Specialist Registrars
Read more Register Here

ELIQUIS® (apixaban) Prescribing Information and Adverse Event Reporting

Risk Minimisation Materials:
Eliquis Prescriber Guide and Patient Alert Card are aimed at increasing awareness about the potential risk of bleeding with apixaban.
More information on each of these documents can be found at
www.medicines.org.uk/emc/product/2878/rmms (5 mg)
or www.medicines.org.uk/emc/product/4756/rmms (2.5 mg).

NVAF
VTE
Duration
1 Hr 15
16
Feb
2022
19:30
  • ELIQUIS®(apixaban) - NVAF & VTE
PP-ELI-GBR-9713. September 2021

The Series - Anticoagulation Stewardship: Pulling Pharmacists Together to Deliver Optimal Patient Care - [Content developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland]

Dr Richard Brown Mr Raj R Patel Miss Alison Freemantle Dr Michael Jackson
Suggested audience
Pharmacists
Read more Register Here

ELIQUIS® (apixaban) Prescribing Information and Adverse Event Reporting

Risk Minimisation Materials:
Eliquis Prescriber Guide and Patient Alert Card are aimed at increasing awareness about the potential risk of bleeding with apixaban.
More information on each of these documents can be found at
www.medicines.org.uk/emc/product/2878/rmms (5 mg)
or www.medicines.org.uk/emc/product/4756/rmms (2.5 mg).

FAQ

See if our frequently asked questions solves your query. If not, use our online enquiry form to get in touch

PP-PFE-GBR-3661. May 2021